Spero Therapeutics (SPRO) Presents At Cantor Healthcare Conference - Slideshow

SPR994: Oral Carbapenem for cUTI - SPR994 requires only a single Phase 3 trial for approval in complicated urinary tract infections (cUTI) and is currently ongoing[9] - The company is fully funded through SPR994 Phase 3 top-line data, with potential additional funding of up to $57 million from BARDA/DTRA[9, 74] - Interim Phase 3 data supports continuing the trial at the selected dose, with top-line data expected in 3Q20[9, 27] - Oral SPR994 could potentially avoid 2.3 million avoidable hospitalizations due to resistance and lack of viable oral cUTI options[15] - The US market opportunity for SPR994 is estimated at $2.9 billion for community UTI and $2.8 billion for hospital UTI[40] Pipeline Expansion - SPR720 is the first oral therapy for NTM infections, with Phase 1 data expected in 4Q19[9, 11] - SPR206 is a novel IV therapy for highly resistant infections, with Phase 1 data also expected in 4Q19[9, 11] Financial Status - As of June 30, 2019, the company had $103.408 million in cash, cash equivalents, and marketable securities[74]